Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0BUURH
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Isotype-AM2
|
|||||
| Synonyms |
Isotype-AM2
Click to Show/Hide
|
|||||
| Organization |
Vor Biopharma Inec.
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Antibody Name |
undisclosed
|
|||||
| Antigen Name |
Receptor-type tyrosine-protein phosphatase C (PTPRC)
|
Antigen Info | ||||
| Payload Name |
Undisclosed
|
|||||
| Therapeutic Target |
Stimulator of interferon genes protein (STING1)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (IC50)Human PBMC | 0.0001 nM | Positive CD45 expression (CD45 +++/++) | ||
| Method Description |
In vitro PBMC killing assays: ADCs conjugated to AM2
|
||||
| In Vitro Model | Normal | PBMC cells | CVCL_0140 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (IC50)Cyno PBMC | 0.0001 nM | Positive CD45 expression (CD45 +++/++) | ||
| Method Description |
In vitro PBMC killing assays: ADCs conjugated to AM2
|
||||
| In Vitro Model | Normal | PBMC cells | CVCL_0140 | ||